Dr. Karen Sims
Chief Medical Officer
Replay available
Arbutus Biopharma Corporation (ABUS) Q3 2024 Earnings Call
Arbutus Biopharma Corporation (NASDAQ: ABUS) Q3 2024 earnings conference call, held 2024-11-06. Replay captured from the company's public earnings webcast.
Hosted by
Featured presenters
Dr. Mike Sophia
Chief Scientific Officer
Mike McElhall
Interim President & Chief Executive Officer
David Hastings
Chief Financial Officer
Lisa Capparelli
Vice President, Investor Relations
Roy Buchanan
Analyst, Citizens JMP
Brian Scorney
Analyst, Baird
Kay Mackey
Analyst, Chardon
Investor webinar replay
Watch the replay and follow the connected company analysis, news, and investor updates for Arbutus Biopharma Corporation.
Replay transcript excerpt
WEBVTT 00:00:00.049 -- 00:00:05.903 Good day and thank you for standing by. Welcome to the Arbutus Biopharma 2024 00:00:05.994 -- 00:00:10.198 third quarter financial results and corporate update. 00:00:10.198 -- 00:00:13.181 At this time, all participants are in listen only mode. 00:00:13.181 -- 00:00:18.244 After the speaker's presentation, there will be a question and answer session. 00:00:18.326 -- 00:00:23.030 To ask a question during this session, you need to press star one one on your telephone. 00:00:23.030 -- 00:00:27.267 You would then hear an automated message advising your hand is raised. 00:00:27.267 -- 00:00:30.948 To withdraw your question, please press star 11 again. 00:00:30.948 -- 00:00:34.589 Please be advised that today's conference is being recorded. 00:00:34.589 -- 00:00:38.609 I would now like to hand the conference over to your first speaker today, Lisa Capparelli, 00:00:38.609 -- 00:00:42.910 Vice President of Investor Relations. Please go ahead. 00:00:42.910 -- 00:00:47.531 Thank you, Antoine. Good morning, everyone, and thank you for joining Arbutus' third 00:00:47.531 -- 00:00:48.952 quarter 2024 00:00:48.952 -- 00:00:51.672 financial results and corporate update call. 00:00:51.672 -- 00:00:56.972 Joining me today from the Arbutus executive team are Mike McElhall, Interim 00:00:56.972 -- 00:01:02.737 President and Chief Executive Officer, David Hastings, Chief Financial Officer, 00:01:02.737 -- 00:01:06.340 Dr. Karen Sims, Chief Medical Officer, and Dr. 00:01:06.340 -- 00:01:09.862 Mike Sophia, Chief Scientific Officer. 00:01:09.862 -- 00:01:15.127 Mike McElhall will provide a corporate update, including an update on our 00:01:15.127 -- 00:01:20.151 ongoing clinical programs in HBV. Dave will then provide a review 00:01:20.151 -- 00:01:23....